Eda Kaya

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 8

Top Topics

Top Venues

Hepatology forum

Rheumatology international

Alimentary pharmacology & therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Ayten Dag, Tumay Ak, Eda Kaya, Zeliha Tulek, Burc Cagri Poyraz, Serdal Uğurlu, Melike Melikoglu, Izzet Fresko, Emire Seyahi
Sexual dysfunction among female patients with rheumatic diseases. Rheumatology international (2024)
Eda Kaya, Guillermo D Mazzolini, Yusuf Yilmaz, Peter Lemmer
Prevention of hepatocellular carcinoma and monitoring of high-risk patients. Hepatology forum 3 (1) (2022)
Eda Kaya, Yusuf Yilmaz
Insidious danger for young adults: Metabolic (dysfunction)-associated fatty liver disease. Hepatology forum 3 (2) (2022)
Hakan Guveli, Tuğçe Özlü, Busra Ersoy Tasar, Emre Batuhan Kenger, Eda Kaya
Sustainability of diet-based moderate calorie restriction among obese patients with metabolic-associated fatty liver disease. Hepatology forum 2 (3) (2021)
Eda Kaya, Alev Bakır Kayı, Haluk Tarik Kani, Coskun Ozer Demirtas, Caglayan Keklikkiran, Yusuf Yilmaz
Simple Noninvasive Scores Are Clinically Useful to Exclude, Not Predict, Advanced Fibrosis: A Study in Turkish Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease. Gut and liver 14 (4) (2021)
Yusuf Yilmaz, Nimet Yılmaz, Fehmi Ates, Fatih Karakaya, Hale Gökcan, Eda Kaya, Gupse Adali, Aysun Caliskan Kartal, Ilker Sen, Emel Ahishali, Seren Ozenirler, Mehmet Koruk, Ahmet Uygun, Ramazan İdilman, null null, null null
The prevalence of metabolic-associated fatty liver disease in the Turkish population: A multicenter study. Hepatology forum 2 (2) (2021)
Eda Kaya, Yusuf Yilmaz
Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver. Journal of clinical and translational hepatology 10 (2) (2021)
Yusuf Yilmaz, Eda Kaya, Fatih Eren
Letter: the use of Fibrosis-4 score in primary care and diabetology practices-Occam's razor applied to advanced fibrosis screening. Alimentary pharmacology & therapeutics 52 (11-12) (2020)